FarmaKology Newsletter - Issue #65

Dec 21, 2020

Today's Startup

BioSyent

BioSyent is a profitable growth-oriented speciality pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are proven safe and effective, and have track records of improving the lives of patients and supporting the healthcare professionals that treat them. Once a product of interest has been found, BioSyent acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

News

Evotec Partners with Alloy Therapeutics to Expand its Antibody Discovery Platform

Evotec SE and Alloy Therapeutics, a biotechnology company dedicated to empowering scientists in the relentless pursuit of making better medicines for all, today announced that the companies have entered into a technology partnership to expand Evotec's antibody discovery platform.

LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes

LanzaTech announced the signing of a new multi-year contract with TeselaGen Biotechnology, extending their relationship through 2025. The two companies have been collaborating since 2016 on the informatics behind high-throughput synthetic biology workflows. Over that time, LanzaTech has continued to experience rapid growth, showing the feasibility to synthesize more than 100 different molecules using its carbon-eating bacteria, and demonstrating the need for a significant scaleup of its R&D operations.

uniQure Announces Clinical Update on Hemophilia B Gene Therapy Program

uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that its haemophilia B gene therapy program, including the pivotal, Phase III HOPE-B study, has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). Patient dosing is complete in each of uniQure’s three haemophilia B gene therapy studies, and there is no plan to enrol or treat additional patients.

ViiV Healthcare announces the Marketing Authorisation of the first complete long-acting injectable HIV treatment in Europe

ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, announced the authorisation of Vocabria (cabotegravir injection and tablets) in combination with Janssen Pharmaceutical Companies of Johnson & Johnson’s Rekambys (rilpivirine injection) and Edurant (rilpivirine tablets), in the European Union, for the treatment of HIV-1 infection in adults who are virologically suppressed.